BECOME A MEMBER
Connect with healthcare professionals around the globe to get the most up-to-date medical cannabis information.
Get Involved
TAKE OUR COURSES
The curriculum brings hands-on practical guidance on how to develop personalized treatment regimens and more.
Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease.
Authors: Cristina Blázquez, Anna Chiarlone, Onintza Sagredo, Tania Aguado, M. Ruth Pazos, et al
Brain, January 2011
—
Endocannabinoids act as neuromodulatory and neuroprotective cues by engaging type 1 cannabinoid receptors. These receptors are highly abundant in the basal ganglia and play a pivotal role in the control of motor behaviour. An early downregulation of type 1 cannabinoid receptor…
A combined preclinical therapy of cannabinoids and temozolomide against glioma.
Authors: Sofía Torres, Mar Lorente, Fátima Rodríguez-Fornés, Sonia Hernández-Tiedra, et al
Molecular Cancer Therapeutics, January 2011
—
Glioblastoma multiforme (GBM) is highly resistant to current anticancer treatments, which makes it crucial to find new therapeutic strategies aimed at improving the poor prognosis of patients suffering from this disease. Δ(9)-Tetrahydrocannabinol (THC), the major active ingred…
Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.
Authors: José Alexandre S Crippa, Guilherme Nogueira Derenusson, Thiago Borduqui Ferrari, et al
Journal of Psychopharmacology, January 2011
—
Animal and human studies indicate that cannabidiol (CBD), a major constituent of cannabis, has anxiolytic properties. However, no study to date has investigated the effects of this compound on human pathological anxiety and its underlying brain mechanisms. The aim of the prese…
Endocannabinoid involvement in endometriosis.
Authors: Natalia Dmitrieva, Hiroshi Nagabukuro, David Resuehr, Guohua Zhang, Stacy McAllister, et al
Pain, December 2010
—
Endometriosis is a disease common in women that is defined by abnormal extrauteral growths of uterine endometrial tissue and associated with severe pain. Partly because how the abnormal growths become associated with pain is poorly understood, the pain is difficult to alleviat…
Use of dronabinol (delta-9-THC) in autism: A prospective single-case-study with an early infantile autistic child.
Authors: René Kurz, Kurt Blaas
Cannabinoids, 21 November 2010
—
Objective: To evaluate the effectiveness of dronabinol (delta-9-THC) as supplementary therapy in a child with autistic disorder. Methods: A child who met the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) criteria for a diagnosis of autistic disorder and who to…
Smoked cannabis for chronic neuropathic pain: a randomized controlled trial.
Authors: Mark A. Ware, Tongtong Wang, Stan Shapiro, Ann Robinson, Thierry Ducruet, Thao Huynh, et al
CMAJ, 5 October 2010
—
BACKGROUND: Chronic neuropathic pain affects 1%-2% of the adult population and is often refractory to standard pharmacologic treatment. Patients with chronic pain have reported using smoked cannabis to relieve pain, improve sleep and improve mood. METHODS: Adults with post-tra…
Cannabis use in palliative care – an examination of the evidence and the implications for nurses.
Authors: Anita J Green, Kay De‐Vries
Journal of Clinical Nursing, September 2010
—
AIM AND OBJECTIVE: Examine the pharmaceutical qualities of cannabis including a historical overview of cannabis use. Discuss the use of cannabis as a clinical intervention for people experiencing palliative care, including those with life-threatening chronic illness such as mu…
Do cannabinoids have a therapeutic role in transplantation?
Authors: Mitzi Nagarkatti, Sadiye Amcaoglu Rieder, Venkatesh L. Hegde, Shunsuke Kanada, et al
Trends in Pharmacological Sciences, August 2010
—
Cannabinoids have emerged as powerful drug candidates for the treatment of inflammatory and autoimmune diseases due to their immunosuppressive properties. Significant clinical and experimental data on the use of cannabinoids as anti-inflammatory agents exist in many autoimmune…
Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis.
Authors: Celia J.A. Morgan, Tom P. Freeman, Gráinne L. Schafer, H. Valerie Curran
Neuropsychopharmacology, August 2010
—
Worldwide cannabis dependence is increasing, as is the concentration of Delta(9)-tetrahydrocannabinol (THC) in street cannabis. At the same time, the concentration of the second most abundant cannabinoid in street cannabis, cannabidiol (CBD), is decreasing. These two cannabino…
Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition.
Authors: María M Caffarel, Clara Andradas, Emilia Mira, Eduardo Pérez-Gómez, Camilla Cerutti, et al
Molecular Cancer, 22 July 2010
—
BACKGROUND: ErbB2-positive breast cancer is characterized by highly aggressive phenotypes and reduced responsiveness to standard therapies. Although specific ErbB2-targeted therapies have been designed, only a small percentage of patients respond to these treatments and most o…
Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion.
Authors: Sarah K. Walsh, Claire Y. Hepburn, Kathleen A. Kane, Cherry L. Wainwright
British Pharmacological Society, July 2010
—
BACKGROUND AND PURPOSE: Cannabidiol (CBD) is a phytocannabinoid, with anti-apoptotic, anti-inflammatory and antioxidant effects and has recently been shown to exert a tissue sparing effect during chronic myocardial ischaemia and reperfusion (I/R). However, it is not known whet…
Cannabinoids, anxiety, and the periaqueductal gray.
Authors: Viviane M. Saito, Fabrício A. Moreira
Psychology & Neuroscience, June 2010
—
The use of Cannabis sativa by humans dates back several thousand years, for both its psychotomimetic and potential medicinal properties. As scientic research methods developed, the cannabinoids present in this herb were characterized, as well as their complex interface wi…